Why did MMTX.SW stock drop today?

MMTX.SW stock fell **-9.00%** on 24 Mar 2026 on heavy volume and no clear earnings catalyst. Low liquidity, profit taking and strong negative momentum readings likely amplified the sell-off.

What is Meyka AI’s rating for MMTX.SW stock?

Meyka AI rates MMTX.SW **62.48/100**, Grade **B — HOLD**. The grade factors in benchmarks, sector performance, financial growth and analyst metrics and is for informational use only.

What are the near-term price forecasts for MMTX.SW stock?

Meyka AI's model projects a downside scenario of **CHF 0.03** (monthly) and a 12-month baseline target of **CHF 0.25**, with respective implied moves of **-92.03%** and **-34.04%** from today’s price.

Which indicators should traders watch for MMTX.SW stock?

Traders should watch **volume**, RSI (**23.86**), ADX (**55.36**), 50/200-day moving averages, and any company updates. A sustained rise in volume with RSI recovery would be an early positive signal.

CH Stocks

MMTX.SW MindMaze Therapeutics (SIX) down 9.00% on 24 Mar 2026: oversold technicals may invite short-term buyers

ByHuzaifa Zahoor March 25, 2026March 25, 2026

MMTX.SW stock fell 9.00% to CHF 0.38 at market close on 24 Mar 2026 after a heavy intraday sell-off. Volume surged to 943,888 shares, more than double the average of 365,908, signalling active liquidation. The decline pushed the share price toward its 52-week low of CHF 0.37. Traders flagged weak momentum and a stretched downtrend, while longer term averages at CHF 0.94 (50-day) and CHF 1.19 (200-day) keep the stock well below key resistance. This report reviews why MMTX.SW stock led the top losers on the SIX session and what investors should watch next.